Scarica l'app Stockscreener
4.46
6.69%
-0.32
Dopo l'orario di chiusura:
4.56
0.10
+2.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
8 Analysts Assess Altimmune: What You Need To Know - Benzinga
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN
PharmAthene stock hits 52-week low at $5.1 amid challenges By Investing.com - Investing.com South Africa
PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo
Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa
Altimmune rises as buyout rumors follow R&D updates - MSN
Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia
Altimmune Outlines Pemvidutide Plans In MASH And Beyond - insights.citeline.com
Altimmune soars amid takeover speculation - MSN
Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha
(ALT) Trading Advice - Stock Traders Daily
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga
Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India
Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK
Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView
Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India
Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa
Citizens JMP reiterates Altimmune stock with $25 target - Investing.com
Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook - TipRanks
Altimmune to test obesity drug for alcohol use disorder and related health conditions - TradingView
Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions - TradingView
Unpartnered Obesity Assets Are Becoming Slim Pickings For Pharma - insights.citeline.com
SBI Securities Co. Ltd. Acquires New Shares in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com Australia
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com South Africa
Altimmune, Inc. to Host Earnings Call - ACCESS Newswire
Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings - Defense World
Altimmune to Host Virtual R&D Day on March 13, 2025 - The Manila Times
Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data - Nasdaq
Can Altimmune's Pemvidutide Transform Both Obesity and MASH Treatment? R&D Day to Reveal Full Potential - StockTitan
Altimmune FY2029 EPS Forecast Decreased by HC Wainwright - Defense World
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):